SGAM
FULC icon

Smith Group Asset Management’s Fulcrum Therapeutics FULC Stock Holding History

Smith Group Asset Management’s Portfolio FULC Stock Details FULC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-520
Closed -$9K – 312
2021
Q4 		$9K Hold
520
– – ﹤0.01% 314
2021
Q3 		$15K Hold
520
– – ﹤0.01% 273
2021
Q2 		$5K Buy
+520
New +$5.26K ﹤0.01% 343

Other funds holding FULC

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
TGI
TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Smith Group Asset Management's FULC Position: Q1 2022 in Review

Smith Group Asset Management sold out of Fulcrum Therapeutics (FULC) in Q1 2022, closing a stake of 520 shares — an estimated $9K sold.

Smith Group Asset Management first reported a position in FULC in Q2 2021 and held it in 3 quarters. The position peaked at $15K in Q3 2021. 108 funds tracked by Wall St. Rank hold FULC as of Q1 2022.

  • Smith Group Asset Management reported no remaining Fulcrum Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Smith Group Asset Management sold 520 Fulcrum Therapeutics shares in Q1 2022, an estimated $9K.
  • Smith Group Asset Management first reported a position in Fulcrum Therapeutics in Q2 2021 and held it in 3 quarters.
  • Smith Group Asset Management's Fulcrum Therapeutics position peaked at $15K in Q3 2021.
  • 108 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q1 2022.

Based on Smith Group Asset Management's 13F filing for Q1 2022, filed 5 May 2022.